About Sermorelin Doctor.

What this site is

Sermorelin Doctor is a casebook on the GHRH(1-29) peptide — a scholarly gathering of the peer-reviewed sermorelin evidence, annotated the way rounds notes are, with every quantitative claim tethered to the study that produced it. The name marks a reading posture toward the literature, not a practice: no patients are seen here, no prescriptions written, and no medical or dosing advice given. The casebook neither sells nor supplies the compound and keeps no clinical staff; it confines itself to what the published record can support.

The "Doctor" in the name is editorial framing, not a claim about services. It names a position the publisher occupies relative to the literature — the measured, reference-monograph register of a work that reads the studies carefully — not a physician, a clinic, or a prescriber. There are no doctors here to consult, no treatment offered, and nothing to fill. There is a reading of the research, organized and cited.

How we read the evidence

The method is consistent across every page: lead with what a study measured, attribute it to the source, and keep the strength of the evidence visible. Where sermorelin's own data is strong — the pediatric height-velocity result ^[1], the older-men GH/IGF-1 reversal ^[2], the pharmacokinetics ^[3] — we say so plainly. Where the popular claims outrun the sermorelin-specific record — adult anti-aging, weight loss, muscle — we mark the gap and name the related-analog or class-level studies that the claims actually rest on ^[5][6]. The goal is a reader who finishes more accurately informed, not more sold.

Regulatory and approval history

Sermorelin's regulatory history is frequently misstated, so this site states it carefully. Sermorelin acetate was an FDA-approved prescription drug for the evaluation and treatment of growth-hormone deficiency and short stature in children. It was withdrawn from the US market in 2008 for commercial reasons — not because of any safety or efficacy problem ^[5]. It is therefore neither a currently-marketed approved finished drug nor a compound that was "never approved": it is a formerly approved GHRH analog, now prepared by compounding pharmacies and treated as a long-standing Category 1 bulk drug substance under FDA's Section 503A framework (final guidance January 2025). This site does not provide regulatory, legal, or medical guidance; this paragraph is a factual summary, and the framing throughout is research-digest, not clinical.

What we do not do

We do not sell sermorelin, recommend a dose, or tell anyone to use it. We do not name vendors or sources of supply. We do not invent authors or clinicians, claim a clinic location, or imply a treatment relationship. Quantitative claims map to the numbered references; where the literature is silent or thin, we say so rather than filling the gap. Sermorelin is prohibited in sport (WADA S2) ^[8], and that, like every other regulatory fact here, is reported as context — not advice.